Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort

BackgroundDialysis patients are at high risk for a severe clinical course after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Safety and early immune responses after mRNA-based vaccination have been reported mostly in patients on hemodialysis (HD), whereas reports of p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Georg Beilhack, Rossella Monteforte, Florian Frommlet, Martina Gaggl, Robert Strassl, Andreas Vychytil
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COVID-19 dialysis antibody response safety mRNA-1273 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/0688098f25fb47eea3a3287e3f9a1a21
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0688098f25fb47eea3a3287e3f9a1a21
record_format	dspace
spelling	oai:doaj.org-article:0688098f25fb47eea3a3287e3f9a1a212021-12-02T08:47:25ZAntibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort1664-322410.3389/fimmu.2021.780594https://doaj.org/article/0688098f25fb47eea3a3287e3f9a1a212021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.780594/fullhttps://doaj.org/toc/1664-3224BackgroundDialysis patients are at high risk for a severe clinical course after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Safety and early immune responses after mRNA-based vaccination have been reported mostly in patients on hemodialysis (HD), whereas reports of peritoneal dialysis (PD) patients remain rare.MethodsIn this retrospective observational study, 39 PD patients had received two doses of the mRNA-1273 Moderna® vaccine. We analyzed SARS-CoV-2 Spike (S) antibody titers 4 weeks after each dose of mRNA-1273 and report local and systemic side effects in PD patients that occurred within one week after each mRNA-1273 dose. Using a quantile regression model we examined factors that might influence SARS-CoV-2 S antibody levels in PD patients.ResultsFour weeks after the first dose of mRNA-1273 vaccine 33 of 39 (84.6%) PD patients seroconverted and presented with 6.62 U/mL (median; IQR 1.57-22.5) anti-SARS-CoV-2 S antibody titers. After the second dose, 38 of 39 (97.4%) PD patients developed anti-SARS-CoV-2 S antibodies and titers increased significantly (median 968 U/mL; IQR 422.5-2500). Pain at the injection site was the most common local adverse event (AE) (71%). Systemic AEs occurring after the first dose were mostly fatigue (33%) and headache (20%). No severe systemic AEs were reported after the first injection. After the second dose the incidence and the severity of the systemic AEs increased. The most common systemic AEs were: fatigue (40.5%), headache (22.5%), joint pain (20%), myalgia (17.5%) and fever (13%). Lower Davies Comorbidity Score (p=0.04) and shorter dialysis vintage (p=0.017) were associated with higher antibody titers after the first dose. Patients with higher antibody titers after the first dose tended to have higher antibody titers after the second dose (p=1.53x10-05).ConclusionsPeritoneal dialysis patients in this cohort had a high seroconversion rate of 97.4%, showed high antibody titers after full vaccination and tolerated the anti-SARS-CoV-2 mRNA-1273 vaccine well without serious adverse events.Georg BeilhackRossella MonteforteFlorian FrommletMartina GagglRobert StrasslAndreas VychytilFrontiers Media S.A.articleCOVID-19dialysisantibody responsesafetymRNA-1273Immunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 dialysis antibody response safety mRNA-1273 Immunologic diseases. Allergy RC581-607
spellingShingle	COVID-19 dialysis antibody response safety mRNA-1273 Immunologic diseases. Allergy RC581-607 Georg Beilhack Rossella Monteforte Florian Frommlet Martina Gaggl Robert Strassl Andreas Vychytil Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
description	BackgroundDialysis patients are at high risk for a severe clinical course after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Safety and early immune responses after mRNA-based vaccination have been reported mostly in patients on hemodialysis (HD), whereas reports of peritoneal dialysis (PD) patients remain rare.MethodsIn this retrospective observational study, 39 PD patients had received two doses of the mRNA-1273 Moderna® vaccine. We analyzed SARS-CoV-2 Spike (S) antibody titers 4 weeks after each dose of mRNA-1273 and report local and systemic side effects in PD patients that occurred within one week after each mRNA-1273 dose. Using a quantile regression model we examined factors that might influence SARS-CoV-2 S antibody levels in PD patients.ResultsFour weeks after the first dose of mRNA-1273 vaccine 33 of 39 (84.6%) PD patients seroconverted and presented with 6.62 U/mL (median; IQR 1.57-22.5) anti-SARS-CoV-2 S antibody titers. After the second dose, 38 of 39 (97.4%) PD patients developed anti-SARS-CoV-2 S antibodies and titers increased significantly (median 968 U/mL; IQR 422.5-2500). Pain at the injection site was the most common local adverse event (AE) (71%). Systemic AEs occurring after the first dose were mostly fatigue (33%) and headache (20%). No severe systemic AEs were reported after the first injection. After the second dose the incidence and the severity of the systemic AEs increased. The most common systemic AEs were: fatigue (40.5%), headache (22.5%), joint pain (20%), myalgia (17.5%) and fever (13%). Lower Davies Comorbidity Score (p=0.04) and shorter dialysis vintage (p=0.017) were associated with higher antibody titers after the first dose. Patients with higher antibody titers after the first dose tended to have higher antibody titers after the second dose (p=1.53x10-05).ConclusionsPeritoneal dialysis patients in this cohort had a high seroconversion rate of 97.4%, showed high antibody titers after full vaccination and tolerated the anti-SARS-CoV-2 mRNA-1273 vaccine well without serious adverse events.
format	article
author	Georg Beilhack Rossella Monteforte Florian Frommlet Martina Gaggl Robert Strassl Andreas Vychytil
author_facet	Georg Beilhack Rossella Monteforte Florian Frommlet Martina Gaggl Robert Strassl Andreas Vychytil
author_sort	Georg Beilhack
title	Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
title_short	Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
title_full	Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
title_fullStr	Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
title_full_unstemmed	Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
title_sort	antibody response and safety after mrna-1273 sars-cov-2 vaccination in peritoneal dialysis patients – the vienna cohort
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/0688098f25fb47eea3a3287e3f9a1a21
work_keys_str_mv	AT georgbeilhack antibodyresponseandsafetyaftermrna1273sarscov2vaccinationinperitonealdialysispatientstheviennacohort AT rossellamonteforte antibodyresponseandsafetyaftermrna1273sarscov2vaccinationinperitonealdialysispatientstheviennacohort AT florianfrommlet antibodyresponseandsafetyaftermrna1273sarscov2vaccinationinperitonealdialysispatientstheviennacohort AT martinagaggl antibodyresponseandsafetyaftermrna1273sarscov2vaccinationinperitonealdialysispatientstheviennacohort AT robertstrassl antibodyresponseandsafetyaftermrna1273sarscov2vaccinationinperitonealdialysispatientstheviennacohort AT andreasvychytil antibodyresponseandsafetyaftermrna1273sarscov2vaccinationinperitonealdialysispatientstheviennacohort
_version_	1718398344476229632

Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort

Ejemplares similares